Практические рекомендации по лечению артериальной гипертензии во время пандемии COVID-19: обзор-2020

Abstract

Arterial hypertension (AH) remains one of the most urgent global health challenges. However, it added up to an equally dangerous challenge - COVID-19 in 2020. That is why the International Society of Hypertension (ISH) released the updated guidelines comprising the methods and drugs that had proven themselves to be the best in the recent randomized controlled trials. In some respects, they differ from the previously issued American and European guidelines, for example, in the very definition for hypertension, which blood pressure threshold should be considered high. However, all three documents are synchronous in terms of drug therapy: it is necessary to start administering antihypertensive drugs as early as possible and immediately use the most effective ones - inhibitors of the renin-angiotensin system (RAS) combined with other drugs that are chosen individually depending on the features of the course of hypertension in each individual patient. In addition, it has been found that RAS inhibitors have a positive effect on the course of COVID-19 in patients with hypertension, which only increased the relevance of the global consensus on hypertension therapy.